Exocrine Pancreatic Insufficiency
A malabsorption condition resulting from greater than 10% reduction in the secretion of pancreatic digestive enzymes (LIPASE; PROTEASES; and AMYLASE) by the EXOCRINE PANCREAS into the DUODENUM. This condition is often associated with CYSTIC FIBROSIS and with chronic PANCREATITIS.
Subtype terms (1)
More specific conditions that are subtypes of Exocrine Pancreatic Insufficiency in the MeSH hierarchy.
- Shwachman-Diamond Syndrome
16 drugs (13 approved, 3 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (2)
Phase 3 trials (1)
Phase 2 trials (7)
Phase 1 trials (5)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (15)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (17)
- Swedish Orphan Biovitrum
- AstraZeneca
- Vivus
- Avanti Polar Lipids, Inc.
- Chiesi
- Nordmark Arzneimittel GmbH & Co. KG
- Parexel
- Cystic Fibrosis Foundation Therapeutics
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Pennsylvania
- Cedars-Sinai Medical Center
- University of Florida
- Mayo Clinic
- University of Cincinnati
- Linical Co., Ltd.
- AzurRx
- AAIPharma
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (5)